Compare FRNM & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRNM | LTGO |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2024 | 2026 |
| Metric | FRNM | LTGO |
|---|---|---|
| Price | $17.01 | $16.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $18.00 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 577.5K | 302.5K |
| Earning Date | N/A | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $236.79 | N/A |
| Revenue Next Year | $11.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.97 | $15.87 |
| 52 Week High | $17.50 | $25.93 |
| Indicator | FRNM | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 33.10 |
| Support Level | $15.28 | $16.19 |
| Resistance Level | $17.34 | $20.49 |
| Average True Range (ATR) | 0.95 | 1.67 |
| MACD | -0.08 | -0.63 |
| Stochastic Oscillator | 83.85 | 6.41 |
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.